Design Therapeutics Inc. (DSGN)
3.88
-0.33 (-7.84%)
At close: Mar 31, 2025, 3:59 PM
3.86
-0.52%
After-hours: Mar 31, 2025, 04:36 PM EDT
-7.84% (1D)
| Bid | 3.61 |
| Market Cap | 220.24M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -49.74M |
| EPS (ttm) | -0.88 |
| PE Ratio (ttm) | -4.41 |
| Forward PE | -4.13 |
| Analyst | Hold |
| Ask | 3.86 |
| Volume | 62,721 |
| Avg. Volume (20D) | 163,435 |
| Open | 4.06 |
| Previous Close | 4.21 |
| Day's Range | 3.85 - 4.10 |
| 52-Week Range | 3.15 - 7.77 |
| Beta | 1.78 |
About DSGN
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysf...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 29, 2021
Employees 54
Stock Exchange NASDAQ
Ticker Symbol DSGN
Website https://www.designtx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for DSGN stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 106.19% from the latest price.
Stock Forecasts10 months ago
+28.49%
Design Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
